| Sep 4 |
Invivyd Doses First Participants in Phase 1 Clinical Trial of VYD2311, a Next Generation Monoclonal Antibody Candidate for COVID-19, Building on the Success of PEMGARDA™
|
| Sep 3 |
Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variants KP.3.1.1 and LB.1, and Other Variants of Interest
|
| Aug 27 |
Invivyd down 18% despite Pemgarda COVID risk reduction data
|
| Aug 27 |
Invivyd Announces PEMGARDA™ (pemivibart) Demonstrated 84% Relative Risk Reduction in Symptomatic COVID-19 Compared to Placebo in an Exploratory Analysis from Ongoing CANOPY Phase 3 Clinical Trial
|
| Aug 21 |
Why Keysight Technologies Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket
|
| Aug 15 |
Invivyd GAAP EPS of -$0.40, revenue of $2.26M
|
| Aug 15 |
Q2 2024 Invivyd Inc Earnings Call
|
| Aug 14 |
Invivyd, Inc. (IVVD) Q2 2024 Earnings Call Transcript
|
| Aug 14 |
Invivyd, Inc. (IVVD) Reports Q2 Loss, Lags Revenue Estimates
|
| Aug 14 |
Invivyd Reports Second Quarter 2024 Financial Results and Recent Business Highlights
|
